BSE in the Friday session
Pharma orchid shares were locked at the top circuit for the 96th consecutive trade day, up 5 percent at Rs 1,839.65 at BSE in the Friday session. This Pharma Stock has been enlarged 102 times or 10,120 percent of the RS 18 level since Relisting on November 3, 2020.
At present, Orchid Pharma is traded under Group T in BSE. In the T2T segment, each trade must produce shipping and no intra-day nets are permitted.
A pharmaceutical company in the process of resolution in the national law tribunal (NCLT)
The company has a total of 40.81 million shares circulating, where 98.04 percent or 40.01 million shares are with promoter Dhanuka laboratory, according to data on stock ownership patterns in December 2020. Dhanuka Laboratories took over the pharmaceutical company in the process of resolution in the national company law tribunal (NCLT).
Shares with financial institutions and banks
Public shareholders are only 1.93 percent holding in the company, where 1.19 percent of shares with financial institutions and banks while individual Pharma Stock shareholders hold 0.51 percent of the shares in the company, data shows.
Leading pharmaceutical companies Pharma Stock in India
Orchid Pharma is one of the leading pharmaceutical companies in India, headquartered in Chennai, and is involved in the development, manufacture, and marketing of active, formulated, and nutraceuticals with exports that cover more than 40 countries.
For the first nine months (April-December) Financial Year 2020-21 (9MFY21) Pharma Stock, Orchid Pharma has reported a net loss of the consolidation of Rs 91.80 Crore as against the loss of Rs 92.21 Crore at 9MFY20. The company has posted a net loss of Rs 131.07 Crore’s consolidation during the entire previous financial year of 2019-20 (FY20).
Implementation of the resolution plan
The new management of the company, while commenting on future prospects in the 2019-20 Year Annual Report (FY20), said that with the implementation of the resolution plan, the company hopes and is confident to achieve an increase in sales and EBITDA (profit before, tax, depreciation, and amortization) During the time.
United States Food and Drug Regulatory Agency (USFDA)
During the FY20 manufacturing facility, API (Active Pharmaceutical Material) located in Tamil Nadu and FDF manufacturing facilities (finished dose form) located in Irukattuktai, Tamil Nadu underwent an inspection by the United States Food and Drug Regulatory Agency (USFDA). The inspection was completed and then the USFDA has issued an Establishment Inspection Report (EIR) for facilities, said the company.
Pharma Stock in the generic formulation domain
In the generic formulation domain, Orchid’s Cumulative abbreviated new drug application (ANDA) Approval in the US market stands at 40. In the European Union (EU), the cumulative amount in the authorization of Active Approval (MA) at 2 in the NPNC segment. In the fire domain (active pharmaceutical material), Orchid’s cumulative from the US DMF stands at 76, it added.
